Hey Wook, if you were a frustrated investor and have been posting for many years wouldn't you target the BOD of Peregrine? I mean, why not, right?

Now, let's say your client was a plaintiff in a class action suit against Peregrine. Wouldn't you put forth a high degree of effort in popular public forums to quell any responsibility of CSM in the NSCLC labeling issue? Because, you want Peregrine to be responsible otherwise it throws your entire case. And wouldn't you characterize Peregrine management as irresponsible - similar to the plaintiff comments in the trial - in an effort to discredit Peregrine? If me, I would cherry pick information and dispute anything positive relating to Peregrine. But, most likely, as soon as my client loses the CA I would probably refrain from posting beyond what I need to do to keep the hounds off the trail.

And if I were IR and were told by lawyers defending our interests in the CA I would feel frustrated. And most likely when investors called me with questions I would feel as though my hands were tied.

Just looking for your perspective on this matter. Thanks.

What frustrates me is the company is withholding a certain tone due to the CA. Even more frustrating is the CA lawyers can have agencies post disparaging remarks against the company on a public forums. We shall see which characters disappear after the judge rules.

Isn't the lawsuit fairly broad in nature pertaining to most things Peregrine? When does your constant challenging stop? I haven't seen your response to Geocappy yet. You respond to everything else though. Why?

Did his response leave you thinking it was not Peregrine holding back but a potential partner? "Material event " wasn't used but a similar boiler plate message. It changed my opinion of IR. We will see if my opinion stands or not.

Edit: cc to Wook. No pm access but I agree with you 100%

CA suit: is it fair to assume that if the judge throws out the CA suit within the next two weeks and the plaintiffs, once again, pursue an appeal, they have an ulterior motive for the suit? Peregrine is up front that this CA is keeping their hands tied. Although, they will tell you they release PR as information is developed - I forget the exact phrasing used in this context. I sure want to see this CA put to rest to know what changes are in store.

IFU, I agree with you about the presentation. One can be respectfully critical - especially having more shares than the CEO has bought outright.

Wook, I know you are an Ameritrade guy. Check the sizzle. It hasn't been this high in a looooong time!

If you are feeling bad about the moving averages you should look at some of the other technicals - you'll feel better about your investment long term. As pointed out before, the weekly CMF is matching that of the period last July before it broke to $5.50. And guess what...it just went GREEN yesterday!!!! The stock has been in oversold territory for over a week. Oh, and those Bollinger bands...

Not only that, short interest has dropped. Institutional interest is increasing. And eventually the stock will follow. So, really, your concern in unnecessary. But thanks anyways.

BD&U, urgency is definitely a factor. I agree. We'll see if it is the CA causing the lack thereof. One consideration is King's use of PLURAL when talking partnering discussions. I believe it is unprecedented if I am not mistaken. This point may be the beginning of what gives a sense of urgency in the market. Okay, obviously not happening today, but we have almost 45 days to end of year. Subtract a few holidays and the weekends and there are, as of today, 32 possible days to announce the partnership or start of phase III trial. One thing in King's presentation was the confidence of starting Phase III before year end. In theory, we should know soon.

After more than six months Peregrine should be in a position to move into Phase III right now, correct? They could possibly be holding back any initiation and enrollment moves because of negotiations. Who knows. I do know that I don't want to get caught on the backside of a partnership. I can risk getting caught with Peregrine starting phase III alone. For what it's worth, that generates a bit of urgency.

25% is a good start. If institutional interest is 50% it would be great. II is incredibly important to stabilize the PPS. We all know this manipulation is tiring.

The best news that was found yesterday was the response from Peregrine to the CA. It brings a bit of confidence that the case will finally be completely dismissed. I firmly believe it is not Peregrine being held back, but it is the potential partners holding off until there is closure with the CA.

I respectfully disagree with those who thought King's presentation was great yesterday. The information was good. Take that out of the equation and the presentation was poor. Think about audience. True, a snake oil salesman is not what one wants. But you need to convince your audience that this is as significant a trigger point in the immunotherapy fight as most here think it is. Highlights were downplayed. Intonation was monotone. And even simple things like King's use of "bavituximab" and "phosphatidylserine" are said so quickly they don't register with the listener. These venues are where you hook the institutional investors. Take them to the breakout rooms and close the deal!

The "multiple partner discussions" is about the only thing new in the presentation. But really what does that mean? Are they discussing at the office in Tustin which BPs they would like to partner with? I feel like I've listened to this same presentation seven times already. King needs to use a little more inflection with the voice. Ugh...

Stoneroad, I read the Phase II status slide and said "what the?" with the Liver trial. Still enrolling?

Little interest in this stock. Not even the naysayers are wasting their time any longer.

Edit: Oh, and yes, I think the company's new stance on the CSM debacle is "labeling issues." One of two things could be construed from that: A) we will never know what/how/where about the mix up, B) the company is "in discussion" with the BP who executed the mix up and won't go out on the limb to point fingers. No justice for those long timers who were screwed September 2012.

Edit 2: After presenting the data for nearly a year with regards to the NSCLC 3mg arm, you would think he would have it engrained in his head! Just venting.

Dia, the presentation better be good. He's been doing it for over 6 months now. Should have it down by now...

The pressure is on for King. These investor conferences are where he can truly impact the share price. I'm not saying he needs to give a "Never Surrender" type speech that makes the share price jump 50%. Instead, he needs to deliver a convincing presentation to get institutional buying higher. Once institutional interest is up, the stock is less vulnerable to the manipulation we're getting on a daily basis.

If King presents virtually the same information he did at Wedbush then what is there for institutions to be excited about? The news last week is about the only additive since then in my opinion.

As pointed out last night, the charts are indicating a buying interest recently that is equivalent to just before the jump from below $1 to $5. Short interest is decreasing and slight increase in institutional ownership as of current reporting (and we need to keep in mind there is potentially a 90 day delay in reporting). I'm encouraged but want to see if King can come through this time.

Edit: $1.29 is seeing a large quantity of 100 share hits. Clear through the ASK and go green for the day.

King is speaking today. He has always brought a confidence in the stock price. (tic of course!)

Short numbers down. Good. Now we just need the institutional buying to support the PPS. The charts (especially CMF) are indicating it could be going on as we speak. Tomorrow Credit Suisse. December Piper Jaffray. Lots happening. News would be primo.

Many investors of PPHM think there are multiple BPs in the mix. By the way, we now have shifted from "partnership" to "collaboration" in terms of BPs. I don't know if that matters, but, "collaboration" seems a better long-term outcome than "partnership." Just my opinion. It could mean nothing at all.

Today's price action has slowed a bit. George's write-up may be losing some steam. The magic number is $1.52. If PPS blasts through that number we know we've got a fish on the line. Probably a marlin not a salmon!

Another biotech feeling the pain today: ZLCS down 73%. Ouch.

A BIG THANKS TO ALL THE VETS OUT THERE!

No, it's playing different today. The hammer came, but there are a whole lotta trades going across at the half penny. I surmise we'll retest the HOD and the shorts will continue covering through the end of day.

Interesting Biopharm. Maybe Peregrine doesn't want to tip off who they are collaborating with in various trials.

Interesting Biopharm. Maybe Peregrine doesn't want to tip off who they are collaborating with in various trials.

Is Abbvie still in the mix of potential partners?

If not Credit Suisse this week at least before Piper Jaffrey. They need to give Duncan something for sticking his neck out for Peregrine. This latest data was good but there's got to be more fire power coming out of Tustin shortly.

Biopharm, you have been pointing to BMS for some time now. It sure looks like Peregrine is doing all they can to release information without tipping their hand too much. The dots in your connect-the-dots diagram are becoming softballs to a baseball player. If, and this is a big IF, BMS does come out of the woodwork as a partner/acquirer of Peregrine, kudos to you. And speaking of boat loads of people relating to Peregrine's stock, is the boiler room closed down today?

I've talked with a number of attorneys and a few executives at my company with a scenario such as Peregrine's class action. The whole CA = no PR thing has me really questioning it. Anyway, the perspective I've not considered is that the partner behind door #1 does not want to get locked in until the CA is finished. It's not Peregrine holding back because of the CA. I didn't think it would have mattered, but from the feedback I got it seems it's a big deal. Peregrine just happens to have their hands tied until the judge rules.

It's nice to have a PR followed with a PPS increase. Let's hope it's the start of a new trend.

EBS, I see it differently. These pre-clinicals lend support to the Phase III about to be launched. Even in the PR they reiterated the Phase III NSCLC. Good to see. As King shifted from "partnering" to "collaboration" in recent cc's I have a feeling bavi will have multiple BPs working with Peregrine. As more data gets released, more interest and, therefore, higher stock price.

I have to think "100% stoppage" is going to attract some attention no matter what stage the trial is.

Also, you and Geo had a good conversation going last night about the plantiff's argument in the CA. One thing I will say is one cannot compare oil drilling with biotech. It should be simple to test one sample of material to determine if it's oil. Testing many thousands of vials of blood samples is a different story. After reading the plantiff's response I still feel strongly about the case being dismissed. My opinion for what it's worth.

I am still not convinced the CA would cause management to withhold information or cause them to change their course. But I cannot wait for closure so I can be proven wrong. These are daytrading hedgefunds taking advantage of PPHM. The stock will recover.

4Our, thanks for the vote of confidence and optimism! It is well-needed on days like these. I've said in the past it takes gonads to invest in PPHM, today it is hurtin' a good one if you know what I mean.

Does anyone recall what specific date the judge is supposed to rule in the CA? Was it Nov 25th?

Hmmmm, I wonder who has the playbook. Normally I would say nice call if it were based on luck. SEC should be on high alert.

Geo, Australia was Lung related only. It wouldn't be prudent for Peregrine to announce something related to Liver, Breast or something different at the Australia convention. We know the game plan for NSCLC, either they go Phase III alone or they attract a partner. I suspect the big splash in Sydney was a last-ditch effort to lock in on a partner. Honestly, I don't have a good feeling about an imminent partnership at this point. It could be that Peregrine has too high of demands (and rightfully so because they were able to corroborate with the FDA after the dose switching) or no BP is willing to give up the US market.

That being said, SITC gives Peregrine the opportunity to announce something new with liver, breast or whatever. The likelihood is small based on historical activities, but all we need is one to change the trend.

King should be ashamed if he goes into the Credit Suisse investor conference saying the same old same old.

Granted Sydney was all about Lung. SITC opens other avenues. But is Peregrine attending? This is tiring.

Is it possible Peregrine just has nothing new to present? Expectations of management performance is becoming lower each day for me.

Thanks for the explanation 4Our. It could be the most logical yet. The CA seems weak and should eventually be cleared, but I do not think Peregrine would be so brazen as to release an earth-moving PR right after a judge clears it. Just my opinion based on management's performance.

We know a public company cannot hold back news without justification so I am still skeptical of Peregrine withholding news because of the CA, but I do appreciate your trying to make sense of it.

4Our and Geo, I've been asking the same question for weeks now; why would Peregrine hold back releasing any news due to CA? It seems the lawsuit against CSM would have more reason for holding back any news. The CA is about actions that took place over a year ago and, in theory, should not hold back the progression of the company. I disagree that a BP would refrain from partnering because of a CA. Does that mean if the CA were not appealed we would be seeing news? There has been nothing new since June 27th.

Maybe the information Oxford had gave them reason to retain the shares despite the $2.43 strike price. HOD on the 2nd line NSCLC surpassed it.

Biopharm, I'm not arguing the use of the ATM, just how it is being used. I don't mind some dilution if it means moving the bavi platform forward. In the end, it could pay dividends if bavi were to become commercialized. Plus, I did say "IF" Lytle were using the ATM strictly in the final days of the quarter. When numbers come out for last quarter we'll see what the average ATM price is. If it is less than $1.32 (share price does not drop below $1.32 the entire quarter until Oct 24), then the company could probably expect more class actions.

However, this could be a huge set up by hedgies to make it look like the company is using the ATM in the final days of the quarter. We all witnessed the unusual deluge of naysayer posters last week. They were trying to beat the spirit out of us. I think it happened for some, but for others it made 'em stronger.

Cheynew, agreed. Lytle has been using the ATM. It appears he has "saved" its use until the final days of the quarter. If (and this is a big IF!) there is any use of ATM today I would speculate a high possibility of another class action lawsuit. If it can be proven that the ATM was used primarily at the end of last quarter and not balanced earlier in the quarter, yet we have ATM working today to put a ceiling on the PPS, we shareholders should be outraged. Of course, positive news on 11/6 would make some of us look the other way.

As someone stated yesterday, with all the attention being drawn upon management antics with the current CAs you would think they would stay clear of anything suspicious.

What's even more interesting are the 100 share lots hitting the bid right after volume goes against the ask. Something is transpiring today.

IFU, Can only be one of two things: shorts covering or tutes buying. This is crazy how the company plays right into their hands. And then the CSOs come on board to bash the BOD when in reality, they love the BOD more than anyone!!!

Eyebuystox, I am not certain of this, but wouldn't the acquirer need to be registered in the same state (CA) as Peregrine in order to take advantage of state tax loss carryovers?

Also, someone (I believe Jake) posted a while back that the removal of the going concern was to stimulate interest from institutions. If that's the case, it's a catch-22 for current shareholders:

- Peregrine needs to use ATM to remain fiscally secure (pushing stock price down). Why not save it all for the end of October to insure point #3 below is in the best interest of employees.
- shorts know Peregrine is going to use the ATM to keep enough cash on hand so they put on the downward pressure
- Peregrine makes little attempt to raise stock price before 11/1 because of ESOP as you point out (reduced support on the buy side)
- Overall market is down. Many biotechs are down between 2 and 6% today.

Man, with all this negative pressure on PPHM you would think we would drop under a dollar. It's a good sign that we've only dropped a dime. There is certain to be a rebound ahead - whether it is 11/4 or a later time is the only uncertainty.

Down day for many biotechs. Shorts are creating opportunity to clear their positions before reporting. I suspect we'll have another day in the low $1.30's. But, Wook, I hope you are right and we bounce back sooner. Seems like a much slower trading day than yesterday though.

Edit: Corp, you cannot take "crickets" as a sign of lack of BOD support. Most people here have you on ignore - and rightfully so.

Wwtmm., you nailed it! That's the problem ; we don't know what they are doing. Communication from Peregrine earns them an "F " in that category.

Please explain to me why that would be. Anyone! There is no reason management should be withholding news because of a CA lawsuit filed about events happening a year ago.

Do we close at $1.385 again today? How is this not obvious to the SEC that the stock price is being manipulated ????